地诺孕素与GnRH-a对卵巢子宫内膜
异位囊肿术后疼痛和复发率的影响

doi:10.3760/cma.j.cn441417-20240311-01006

摘要/Abstract

摘要： 目的　比较卵巢子宫内膜异位囊肿（OEC）剔除术后辅以地诺孕素与促性腺激素释放激素激动剂（GnRH-a）治疗后患者疼痛和疾病复发率的差异。方法　本研究为随机对照试验。依据随机硬币投掷法，将2020年5月至2022年4月西电集团医院妇产科符合OEC剔除术治疗标准的113例患者分为 GnRH-a 组（61例）和地诺组（52例）。GnRH-a 组年龄（35.38±4.49）岁；病程（3.28±1.04）年；囊肿大小 6.00（5.00，8.00）cm；美国生殖医学学会（American Society for Reproductive Medicine，ASRM）分期：Ⅰ～Ⅱ期 30 例，Ⅲ～Ⅳ期 31 例。地诺组年龄（35.52±4.61）岁；病程（3.52±1.06）年；囊肿大小 6.00（5.00，8.00）cm；ASRM分期：Ⅰ～Ⅱ期26例，Ⅲ～Ⅳ期26例。从剔除术后首次月经来潮的第1天开始，GnRH-a组采用腹前壁皮下注射醋酸亮丙瑞林进行辅助治疗，3.75 mg/次，4周一次；地诺组口服地诺孕素片进行辅助治疗，2 mg/次，每天一次。两组均持续治疗 24 周。比较两组视觉模拟评分法（VAS）评分、不良反应、复发率和治疗满意度。采用独立样本 t 检验、非参数 Wilcoxon 检验、 Mann-Whitney U检验、χ2 检验进行统计学分析。结果　用药24周后，地诺组痛经、慢性盆腔痛和性交痛 VAS 评分均低于 GnRH-a 组［0.50（0，2.00）分比1.00（0，3.00）分，1.00（0，3.00）分比2.00（1.00，4.00）分， 0（0，2.00）分比 1.00（0，2.00）分］（Z=2.396、2.669、2.929，均 P<0.05）。GnRH-a组和地诺组不良反应发生率和停药后 12个月复发率比较［14.75%（9/61）比 5.77%（3/52），8.20%（5/61）比 1.92%（1/52）］，差异均无统计学意义（χ2 =2.378、2.197，均 P>0.05）。地诺组治疗总满意度高于 GnRH-a组［94.23%（49/52）比 81.97%（50/61）］（χ2 =3.889，P<0.05）。结论　相较于 GnRH-a，OEC 剔除术后辅以地诺孕素能有效缓解患者疼痛，预防疾病复发，获得更高的治疗满意度。

关键词:

卵巢子宫内膜异位囊肿, 剔除术, 地诺孕素, 促性腺激素释放激素激动剂, 疼痛, 复发

Abstract:

Objective　To compare the differences of pain and disease recurrence rates in patients after ovarian endometriosis cyst (OEC) excision treated with dienogest and gonadotropin-releasing hormone agonist (GnRH-a). Methods　This study was a randomized controlled trial. According to the random coin toss method, 113 patients who met the treatment criteria of OEC excision in the Department of Obstetrics and Gynecology of XD Group Hospital from May 2020 to April 2022 were divided into a GnRH-a group (61 cases) and a dienogest group (52 cases). The age of the GnRH-a group was (35.38±4.49) years old, the course of disease was (3.28±1.04) years, the cyst size was 6.00 (5.00, 8.00) cm, and the American Society for Reproductive Medicine (ASRM) staging was stage Ⅰ to Ⅱ in 30 cases and stage Ⅲ to Ⅳ in 31 cases. The age of the dienogest group was (35.52±4.61) years old, the course of disease was (3.52±1.06) years, the cyst size was 6.00 (5.00, 8.00) cm, and the ASRM staging was stage Ⅰ to Ⅱ in 26 cases and stage Ⅲ to Ⅳ in 26 cases. From the first day of the first menstrual period after OEC excision, the GnRH-a group was treated with subcutaneous injection of leuprelin acetate in the anterior abdominal wall, 3.75 mg/time, once every 4 weeks; the dienogest group received oral dienogest tablets, 2 mg/time, once a day. Both groups were treated for 24 weeks. The Visual Analogue Scale (VAS) score, adverse reactions, recurrence rate, and treatment satisfaction were compared between the two groups. Independent sample t test, non-parametric Wilcoxon test, Mann-Whitney U test, and χ² test were used for statistical analysis. Results　After 24 weeks of treatment, the VAS scores of dysmenorrhea, chronic pelvic pain, and sexual pain in the dienogest group were lower than those in the GnRH-a group [0.50 (0, 2.00) points vs. 1.00 (0, 3.00) points, 1.00 (0, 3.00) points vs. 2.00 (1.00, 4.00) points, 0 (0, 2.00) points vs. 1.00 (0, 2.00) points] (Z=2.396, 2.669, and 2.929, all P<0.05). There was no statistically significant difference in the incidence of adverse reactions or the recurrence rate within 12 months after withdrawal between the GnRH-a group and the dienogest group [14.75% (9/61) vs. 5.77% (3/52), 8.20% (5/61) vs. 1.92% (1/52)] (χ²=2.378 and 2.197, both P>0.05). The total satisfaction of the dienogest group was higher than that of the GnRH-a group [94.23% (49/52) vs. 81.97% (50/61)] (χ²=3.889, P<0.05). Conclusion　Compared with GnRH-a, supplement of dienogest after OEC excision can more effectively relieve the patients' pain, prevent the disease recurrence, and obtain higher treatment satisfaction.

Key words:

Ovarian endometriosis cyst, , Excision, Dienogest, Gonadotropin releasing hormone agonist, Pain, Recurrence

张秀玲韩志红戴旭. 地诺孕素与GnRH-a对卵巢子宫内膜异位囊肿术后疼痛和复发率的影响[J]. 国际医药卫生导报, 2025, 31(1): 26-30.

Zhang Xiuling , Han Zhihong , Dai Xu. Effects of dienogest and GnRH-a on postoperative pain and recurrence rate of ovarian endometriosis cyst [J]. International Medicine and Health Guidance News, 2025, 31(1): 26-30.

参考文献

[1] 马昕,纪婷.血清可溶性细胞间黏附分子1和凝血指标检测对卵巢子宫内膜异位囊肿患者腹腔镜卵巢囊肿剔除术后复发的预测价值[J].陕西医学杂志,2023,52(2):208-211,216. DOI:10.3969/j.issn.1000-7377.2023.02.021.
[2] 国家放射与治疗临床医学研究中心,中华医学会超声分会超声介入学组,中国医师协会介入医师分会超声介入委员会,等.卵巢子宫内膜异位囊肿超声引导穿刺硬化治疗专家共识[J].中华超声影像学杂志,2020,29(12):1013-1024. DOI:10.3760/cma.j.cn131148-20200814-00658.
[3] 杨露,高建宏,韩洁,等.卵巢子宫内膜异位囊肿不孕患者腹腔镜术后妊娠影响因素分析及EFI评分的预测价值[J].中国计划生育学杂志,2022,30(6):1374-1378. DOI:10.3969/j.issn.1004-8189.2022.06.035.
[4] 周冬梅,汤云仙,冯冠男,等.CA125、CA199及HE4联合检测对卵巢子宫内膜异位囊肿破裂的诊断[J].中南民族大学学报(自然科学版),2022,41(5):542-546. DOI:10.12130/znmdzk.20220505.
[5] 周芮,骆丽娜,李雪岩.卵巢子宫内膜异位囊肿术后复发患者临床特征及GnRH-a联合腹腔镜手术疗效[J].中国计划生育学杂志,2023,31(3):636-640,645. DOI:10.3969/j.issn.1004-8189.2023.03.032.
[6] 江燕,叶仁丽,魏明.腹腔镜下卵巢子宫内膜异位囊肿剥除术后复发率及其影响因素分析[J].中国性科学,2023,32(3):109-112. DOI:10.3969/j.issn.1672-1993.2023.03.027.
[7] Koga K, Osuga Y, Takemura Y, et al. Recurrence of endometrioma after laparoscopic excision and its prevention by medical management[J]. Front Biosci (Elite Ed), 2013, 5(2):676-683. DOI: 10.2741/e648.
[8] 师瑶,段君熠,赵烨.卵巢子宫内膜异位囊肿术后复发危险因素及药物治疗研究进展[J].实用药物与临床,2022,25(9):843-847. DOI:10.14053/j.cnki.ppcr.202209017.
[9] 李利荣,吕淑兰.子宫内膜异位症术后应用GnRH-α的疗效观察[J].中国妇幼健康研究,2019,30(3):354-358. DOI:10.3969/j.issn.1673-5293.2019.03.022.
[10] 童巧玲,宋芳,沈姣梅.复方玄驹胶囊联合腹腔镜保守手术对子宫内膜异位症患者的临床疗效[J].中成药,2023,45(7):2454-2456. DOI:10.3969/j.issn.1001-1528.2023.07.062.
[11] 刘玲,方春丽,陈红霞.卵巢子宫内膜异位囊肿术后使用GnRHa及LNG-IUS预防复发的临床疗效[J].江苏医药,2019,45(4):359-361. DOI:10.19460/j.cnki.0253-3685. 2019.04.011.
[12] 段利利,李志斌,张婵,等.地诺孕素在子宫内膜异位症中的治疗效果[J].中国妇幼健康研究,2021,32(6):909-913. DOI:10.3969/j.issn.1673-5293.2021.06.024.
[13] 王久兰,何伟,周夏伶,等.地诺孕素、亮丙瑞林辅助治疗卵巢子宫内膜异位囊肿的临床效果比较[J].中国妇产科临床杂志,2022,23(3):275-277. DOI:10.13390/j.issn.1672- 1861.2022.03.017.
[14] 谢幸,孔北华,段涛.妇产科学[M].9版.北京:人民卫生出版社,2018:301-304.
[15] 刘亚妮,符雅惠,孟凡峰.补肾化瘀汤联合米非司酮治疗卵巢子宫内膜异位症临床观察[J].陕西中医,2017,38(10):1343-1344. DOI:10.3969/j.issn.1000-7369.2017.10.011.
[16] 董珍珠,谢熙,毛晓丹.子宫内膜异位症患者抗苗勒管激素基础水平研究进展[J].国际妇产科学杂志,2017,44(2):228-231,封3. DOI:10.3969/j.issn.1674-1870.2017. 02.027.
[17] 时娟娟,杜超,韩珊珊,等.34例儿童卵巢肿块临床特点及热点问题[J].国际医药卫生导报,2023,29(8):1080-1085. DOI:10.3760/cma.j.issn.1007-1245.2023.08.011.
[18] Stuparich MA, Donnellan NM, Sanfilippo JS. Endometriosis in the adolescent patient[J]. Semin Reprod Med, 2017, 35(1):102-109. DOI: 10.1055/s-0036- 1597121.
[19] 戴毅,冷金花,郎景和,等.卵巢内异症囊肿患者盆腔病灶的解剖特征及其与疼痛的关系[J].中华妇产科杂志,2013,48(2):118-122. DOI:10.3760/cma.j.issn.0529- 567x.2013.02.008.
[20] Guo SW. Recurrence of endometriosis and its control[J]. Hum Reprod Update, 2009, 15(4):441-461. DOI: 10.1093/humupd/dmp007.
[21] Han S, Lee H, Kim S, et al. Risk factors related to the recurrence of endometrioma in patients with long-term postoperative medical therapy[J]. Ginekol Pol, 2018, 89(11):611-617. DOI: 10.5603/GP.a2018.0105.
[22] 孙利娟,李涛,张琼.腹腔镜术后醋酸戈舍瑞林缓释植入剂治疗卵巢型子宫内膜异位症临床疗效及术后复发相关因素分析[J].中国计划生育学杂志,2022,30(11):2537-2542. DOI:10.3969/j.issn.1004-8189.2022.11.024.
[23] Zakhari A, Edwards D, Ryu M, et al. Dienogest and the risk of endometriosis recurrence following surgery: a systematic review and meta-analysis[J]. J Minim Invasive Gynecol, 2020, 27(7):1503-1510. DOI: 10.1016/j.jmig.2020.05.007.
[24] Gruber TM, Mechsner S. Pathogenesis of endometriosis: the origin of pain and subfertility[J]. Cells, 2021, 10(6):1381. DOI: 10.3390/cells10061381.
[25] 罗艳,林丹玫,吴茜,等.基于网络药理学的地诺孕素治疗子宫内膜异位症的机制探讨[J].中国妇幼保健,2023,38(4):591-596. DOI:10.19829/j.zgfybj.issn.1001-4411.2023. 04.003.
[26] 任虹阳,刘曼玉,董茜文,等.地诺孕素在子宫内膜异位症药物治疗中的新进展[J].中国妇幼保健,2023,38(19):3839-3842. DOI:10.19829/j.zgfybj.issn.1001-4411.2023. 19.058.